Insider buying last 90 days
No open-market insider purchases were filed for ORKA in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every ORKA insider filing, plotted on the chart in Gekko.Open ORKA in Gekko
NASDAQ: ORKA
Oruka Therapeutics (ORKA) Stock Analysis & Forecast
Sep 28 close
$84.19−0.27 (−0.3%)
Gekko Brief
AI summaryOruka Therapeutics moved this week on clinical trial news for ORKA-001, its psoriasis drug. The company reported positive week 28 data from the ongoing EVERLAST-A trial, with PASI 100 increasing to 71.4% and PASI 90 to 87.3%, showing deepening responses without additional dosing, and a favorable safety and tolerability profile maintained through week 28. Despite this positive efficacy data, shares fell 5% amid the report, with safety disclosures apparently weighing on the stock even as the underlying trial results were described as positive.
ORKA closed at $84.19, down 0.3%, with the stock sitting between its 50-day average of $96.50 and its 200-day average of $62.87. The GekkoIndex reads 67.9, placing the stock in the Accumulation zone. Price sits 23.4% below Gekko Fair Value of $109.88. The stock's one-month return stands at -12.8%, though its six-month return remains at 89.3% and its one-year return at 459.4%.
Looking ahead, Oruka's next earnings report is scheduled for 11 November 2026, 43 days away, placing it outside a typical 20-trading-day holding window. The prior quarter saw an EPS beat, with actual results of -0.55 against an estimate of -0.49, producing a 5.9% price reaction. Seasonality data shows the next 20 trading days have averaged an 18.6% return over 5 years, though gains occurred in only 2 of those years. Eleven analysts currently rate the stock a buy, with a consensus target of $155.00.
Written by AI and checked automatically against the figures on this page. Generated Sep 29, 2026 from the data above.
Oruka Therapeutics price vs fair value
Close $84.19200-day averageGekko Fair Value $109.88
Oruka Therapeutics quick facts
- Market cap
- $5.08B
- P/E ratio
- —
- Forward P/E
- —
- EPS, TTM
- −$2.04
- Revenue, TTM
- $0
- Profit margin
- 0%
- Dividend yield
- —
- Beta
- -0.21
- Volume
- 923,248 avg 939,179
- 1-year return
- +459.4%
- Typical daily move
- ±5.6%
- Typical 20-day move
- ±7.5%
- 50-day average
- $96.50
- 200-day average
- $62.87
- Next earnings
- Nov 11
- Shares outstanding
- 66.21M
Oruka Therapeutics swing-trade checklist
Oruka Therapeutics scores 3 supportive, 2 mixed and 0 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive2 mixed0 headwinds
- Trendmixed
Averages disagree
Close $84.19 sits between the 50-day ($96.50) and 200-day ($62.87) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
67.9, Accumulation
Reading 67.9 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
23.4% below
Price is 23.4% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 43 days
Next report Nov 11, 2026, 43 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitymixed
+18.6% on average
From this point in the calendar, the next 20 trading days averaged +18.6% over 5 years, rising in 2 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Oruka Therapeutics stock chart and price history
Oruka Therapeutics closed at $84.19 on Sep 28, 2026, +459.4% over the past year, inside a 52-week range of $15.00 to $115.52.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −12.8%
- 3 months
- −9.0%
- 6 months
- +89.3%
- 1 year
- +459.4%
The full ORKA chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open ORKA in Gekko
Follow Oruka Therapeutics through every session
Put ORKA on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track ORKA in GekkoFree for 7 days. No credit card required.
About Oruka Therapeutics
Oruka Therapeutics is a clinical-stage biopharmaceutical company working on monoclonal antibody treatments for psoriasis and related inflammatory and immunology conditions. Its work centers on a set of drug candidates aimed at underlying immune pathways linked to these diseases, with the goal of offering new treatment options to patients affected by them.
The company's pipeline includes ORKA-001, aimed at the p19 subunit of interleukin-23 and currently in a phase 2a trial for psoriasis, and ORKA-002, which targets both interleukin-17A and interleukin-17F and is being tested in a phase 2 trial for psoriasis, psoriatic arthritis, and other conditions. It is also developing ORKA-003, aimed at a pathway that has not been disclosed, along with ORKA-021, a regimen that combines ORKA-002 and ORKA-001 in sequence.
Oruka Therapeutics is headquartered in Menlo Park, California, and its shares are listed on the NASDAQ under the ticker ORKA.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Website
- orukatx.com
Oruka Therapeutics GekkoIndex: the smart money zone
Oruka Therapeutics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 67.9, in the Accumulation zone, up 7.7 points over five sessions.
67.9Accumulation
Up 7.7 points over five sessions.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days |
|---|---|---|---|
| Buying | 41 | +3.1% | +3.1% |
| Accumulation (current zone) | 158 | +0.4% | +0.9% |
| Neutral | 407 | +2.7% | +11.0% |
| Distribution | 56 | +1.6% | +13.2% |
| Selling | 10 | −7.5% | −12.0% |
Average ORKA share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.3% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the ORKA price, zone by zone.Track ORKA in Gekko
Is Oruka Therapeutics stock overvalued? Gekko Fair Value
Oruka Therapeutics trades 23.4% below Gekko Fair Value of $109.88, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Oruka Therapeutics shares are worth, recalculated every trading day.
$109.88
Gekko Fair Value, Sep 26, 2026
23.4% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open ORKA in Gekko
Oruka Therapeutics insider and Congress trading
No open-market insider purchases were filed for Oruka Therapeutics, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in ORKA were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for ORKA, plotted on the chart in Gekko.Open ORKA in Gekko
Hedge funds and billionaires quarter ended Jun 30
2of the funds Gekko tracks hold ORKA.
0added1opened1trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko
Oruka Therapeutics earnings: next date and track record
Oruka Therapeutics reports on Nov 11, 2026 (43 days away), and beat the EPS estimate in 5 of its last 8 reports.
Next earnings report
Nov 11, 2026
43 days away
- EPS estimate
- −$0.60
5 of 8reports beat the EPS estimate
±5.9%average move across the report
4 of 8reports followed by a gain
Share-price move across each report
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 10, 2026 | −$0.55 est −$0.49 | — | +5.9% |
| May 13, 2026 | −$0.48 est −$0.54 | — | −1.2% |
| Mar 12, 2026 | −$0.45 est −$0.62 | — | +16.2% |
| Nov 12, 2025 | −$0.55 est −$0.56 | — | −6.5% |
| Aug 11, 2025 | −$0.46 est −$0.48 | — | +6.6% |
| May 14, 2025 | −$0.40 est −$0.44 | — | −1.7% |
| Mar 6, 2025 | −$0.54 est −$0.41 | — | +0.8% |
| Nov 13, 2024 | −$1.46 est −$0.32 | — | −8.0% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Oruka Therapeutics stock forecast and analyst price targets
Analysts’ average 12-month price target for Oruka Therapeutics is $155.00, +84.1% from the last close, from 11 firms rating the stock in the last 90 days.
$155.00consensus 12-month target, +84.1% from the last close
Now $84.19Avg $155.00
Low $120High $200
Each firm’s latest rating in the last 90 days: 11 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 24 | H.C. Wainwright | $120 | +42.5% |
| Sep 24 | Wedbush | $165 | +96.0% |
| Sep 23 | LifeSci Capital | $175 | +107.9% |
| Sep 23 | Clear Street | $131 | +55.6% |
| Sep 21 | Barclays | $160 | +90.0% |
+0.9%average 20-day move after past Accumulation readings
+18.6%average move over the next 20 trading days in the last 5 years
±5.6%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Oruka Therapeutics seasonality: the next 20 trading days
Over the next 20 trading days from Sep 26, Oruka Therapeutics averaged +18.6% across the last 5 years, rising in 2 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +6.7% | 3 of 5 |
| Next 10 trading days | +14.2% | 3 of 5 |
| Next 15 trading days | +19.4% | 4 of 5 |
| Next 20 trading days | +18.6% | 2 of 5 |
| Next 30 trading days | +15.9% | 2 of 5 |
For scale, ORKA’s typical 20-trading-day move in either direction is about 7.5%.
Oruka Therapeutics market cap and key statistics
Oruka Therapeutics’s market cap is $5.08B and revenue of $0 over the last twelve months.
Valuation
- Market cap
- $5.08B
- EPS, TTM
- −$2.04
- Gekko Fair Value
- $109.88
Trading
- Volume
- 923,248
- Avg volume, 20 days
- 939,179
- 52-week high
- $115.52
- 52-week low
- $15.00
- Shares outstanding
- 66.21M
Financials
- Revenue, TTM
- $0
- Profit margin
- 0%
- Return on equity
- -18.2%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- -0.21
- Typical daily move
- ±5.6%
- Typical 20-day move
- ±7.5%
Oruka Therapeutics stock news this week
3 headlines about Oruka Therapeutics from the past week, newest first, each linking to the publisher.
- ORKA Stock Down 5% Despite Positive Week 28 Psoriasis Efficacy DataZacks Investment Research, Sep 24
- Oruka Therapeutics Says Psoriasis Drug Shows Deepening EfficacyBenzinga, Sep 23
- Oruka Therapeutics Announces Positive Week 28 Data for ORKA-001 from the Ongoing EVERLAST-A Trial Showing Deepening of Responses Without Additional DosingGlobeNewsWire, Sep 23
Oruka Therapeutics peers
Oruka Therapeutics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 17.9% above |
| JNJJohnson & Johnson | Neutral | 0.5% above |
| ABBVAbbVie | Neutral | 23.3% above |
| MRKMerck | Neutral | 4.2% below |
| AZNAstraZeneca | Neutral | 39.9% below |
| PFEPfizer | Neutral | 4.0% below |
A peer links to its own page where one exists.
Oruka Therapeutics stock FAQ
What is Oruka Therapeutics’s market cap?
Oruka Therapeutics’s market cap is $5.08B at the Sep 28, 2026 close of $84.19, with 66.21M shares outstanding.
What is the Oruka Therapeutics stock forecast?
The consensus analyst 12-month price target for Oruka Therapeutics is $155.00, +84.1% from the last close. Of the 11 firms that rated the stock in the last 90 days, 11 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Oruka Therapeutics stock overvalued or undervalued?
On Gekko’s estimate Oruka Therapeutics is undervalued: the Sep 28, 2026 close of $84.19 is 23.4% below Gekko Fair Value of $109.88. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Oruka Therapeutics report earnings next?
Oruka Therapeutics is expected to report on Nov 11, 2026 (43 days away). Analysts expect earnings of −$0.60 per share. Oruka Therapeutics beat the earnings estimate in 5 of its last 8 reports, moving 5.9% on average across the report.
What is Oruka Therapeutics’s 52-week high and low?
Oruka Therapeutics’s 52-week high is $115.52 and its 52-week low is $15.00; it closed at $84.19 on Sep 28, 2026, +459.4% over the past year.
Is Oruka Therapeutics stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (gekkoindex, fair value and earnings risk), 2 as mixed (trend and seasonality). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Oruka Therapeutics the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.